1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66F79F88AF843C3A000258568003CB8AD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-oversight-management-investigator-initiated-trials-resource-allocation-communication-future-prospects?opendocument
18
19opendocument
2018.206.194.134
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Clinical Trials

Best Practices in the Management of Investigator Initiated Trials: Resource Allocation, Communication and Future Prospects

ID: 5615


Features:

4 Info Graphics

20 Data Graphics

330+ Metrics

4 Narratives


Pages/Slides: 35


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in the Management of Investigator Initiated Trials: Resource Allocation, Communication and Future Prospects”

STUDY OVERVIEW


With the biopharmaceutical industry utilizing investigator-initiated trials (IITs) to increase the breadth of clinical programs, it is critical that organizations don't let costs leapfrog results.

Thus as companies accelerate their IIT programs, it is important that they appropriately resource and effectively manage communications with investigators.

Best Practices, LLC undertook this benchmarking research to provide a detailed roadmap for improving IIT management at bio-pharmaceutical companies, capturing critical metrics and insights on IIT management team staffing, budget and communication. This study also identifies the top challenges and future improvements to IIT management process.


KEY TOPICS

  • IIT Funding
  • Future Improvements
  • Challenges

KEY METRICS
  • Please specify the number of FTEs dedicated to IIT management at your company
  • What was your total budget for IIT management in the last fiscal year ($USD)?
  • How many IITs were included in your total budget in the last fiscal year?
  • If there are multiple Investigators submitting similar proposals, does your organization allow introducing these Investigators to each other in case they may be interested in collaborating?
  • Does your company require publication (abstract or peer review manuscript) as a condition for final milestone payment?
  • What are the top challenges to IIT management process?
  • How do you plan to improve your IIT management process?

SAMPLE KEY FINDINGS
  • Companies are requiring more frequent IIT updates
    • Cycle times are shrinking for key IIT categories, such as (1) protocol review to protocol decision; (2) protocol decision to contract negotiation start, and (3) contract execution to first patient in study.
    • The percent of company staff fully dedicated to IIT management has risen by 30% from 2017 to 2020, which may partially explain how IIT cycle times are being compressed.
METHODOLOGY

Best Practices, LLC engaged 46 leaders from 34 bio-pharmaceutical and medical device companies in this research through a benchmarking survey. Nearly three-fourths of the respondents serve at the director level or above.


Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Allergan; Arena Pharmaceuticals; Bayer; Beckman Coulter; Becton Dickinson; Biofrontera; Bioventus; Blue Earth Diagnostics; Cipla; Daiichi Sankyo; Edwards Lifesciences; Eisai; EMD Serono; Fidia; Gedeon Richter ; Grifols; Guerbet; Ipsen; Jazz Pharmaceuticals; Julphar; Karyopharm Therapeutics; Lundbeck; Merck; Merz Pharma; Novartis; Sage Therapeutics; Sandoz; Sanofi; Santen; Seqirus; Solidfarma; Takeda Pharmaceuticals; Terumo Corporation

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.